10-Q Filing

AGIOS PHARMACEUTICALS, INC. CIK: 1439222 Q2 2022

Filing Information

Form Type	10-Q
Accession Number	`0001439222-22-000070`
Period End Date	20220630
Filing Date	20220804
Fiscal Year	2022
Fiscal Period	Q2
XBRL Instance	agio-20220630_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 80 Income Statement 82 Cash Flow Statement 86 Stockholders Equity 34 Comprehensive Income 14

Balance Sheet 80 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value (in usd per share)	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, par value (in usd per share)	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	25.00M	shares	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	25.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$88.54M	USD	Point-in-time
Preferred stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$203.13M	USD	Point-in-time
Marketable securities	`AvailableForSaleSecuritiesDebtSecuritiesCurrent`	$730.77M	USD	Point-in-time
Marketable securities	`AvailableForSaleSecuritiesDebtSecuritiesCurrent`	$816.89M	USD	Point-in-time
Preferred stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Common stock, par value (in usd per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Accounts receivable, net	`ContractWithCustomerAssetNetCurrent`	$1.60M	USD	Point-in-time
Accounts receivable, net	`ContractWithCustomerAssetNetCurrent`	-	USD	Point-in-time
Common stock, par value (in usd per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Other receivable	`OtherReceivablesNetCurrent`	$2.70M	USD	Point-in-time
Other receivable	`OtherReceivablesNetCurrent`	$4.38M	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	125.00M	shares	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	125.00M	shares	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	70.55M	shares	Point-in-time
Inventory	`InventoryNet`	$4.06M	USD	Point-in-time
Inventory	`InventoryNet`	-	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	71.03M	shares	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	54.82M	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$42.34M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$39.84M	USD	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	54.33M	shares	Point-in-time
Treasury stock, shares (in shares)	`TreasuryStockShares`	16.22M	shares	Point-in-time
Treasury stock, shares (in shares)	`TreasuryStockShares`	16.22M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$870.01M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$1.06B	USD	Point-in-time
Marketable securities	`AvailableForSaleSecuritiesDebtSecuritiesNoncurrent`	$280.85M	USD	Point-in-time
Marketable securities	`AvailableForSaleSecuritiesDebtSecuritiesNoncurrent`	$266.38M	USD	Point-in-time
Operating lease assets	`OperatingLeaseRightOfUseAsset`	$75.12M	USD	Point-in-time
Operating lease assets	`OperatingLeaseRightOfUseAsset`	$70.21M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$28.92M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$27.38M	USD	Point-in-time
Financing lease assets	`FinanceLeaseRightOfUseAsset`	$183.00K	USD	Point-in-time
Financing lease assets	`FinanceLeaseRightOfUseAsset`	$64.00K	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$3.96M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$2.90M	USD	Point-in-time
Total assets	`Assets`	$1.44B	USD	Point-in-time
Total assets	`Assets`	$1.25B	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$16.70M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$7.79M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$28.38M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$31.97M	USD	Point-in-time
Operating lease liabilities	`OperatingLeaseLiabilityCurrent`	$10.83M	USD	Point-in-time
Operating lease liabilities	`OperatingLeaseLiabilityCurrent`	$12.06M	USD	Point-in-time
Financing lease liabilities	`FinanceLeaseLiabilityCurrent`	$167.00K	USD	Point-in-time
Financing lease liabilities	`FinanceLeaseLiabilityCurrent`	$331.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$48.40M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$59.83M	USD	Point-in-time
Operating lease liabilities, net of current portion	`OperatingLeaseLiabilityNoncurrent`	$78.95M	USD	Point-in-time
Operating lease liabilities, net of current portion	`OperatingLeaseLiabilityNoncurrent`	$85.66M	USD	Point-in-time
Other non-current liabilities	`OtherLiabilitiesNoncurrent`	$1.05M	USD	Point-in-time
Other non-current liabilities	`OtherLiabilitiesNoncurrent`	$276.00K	USD	Point-in-time
Total liabilities	`Liabilities`	$145.76M	USD	Point-in-time
Total liabilities	`Liabilities`	$128.40M	USD	Point-in-time
Preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued or outstanding at June 30, 2022 and December 31, 2021	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued or outstanding at June 30, 2022 and December 31, 2021	`PreferredStockValue`	-	USD	Point-in-time
Common stock, $0.001 par value; 125,000,000 shares authorized; 71,031,792 shares issued and 54,815,381 shares outstanding at June 30, 2022, and 70,550,631 shares issued and 54,334,220 shares outstanding at December 31, 2021	`CommonStockValue`	$71.00K	USD	Point-in-time
Common stock, $0.001 par value; 125,000,000 shares authorized; 71,031,792 shares issued and 54,815,381 shares outstanding at June 30, 2022, and 70,550,631 shares issued and 54,334,220 shares outstanding at December 31, 2021	`CommonStockValue`	$71.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$2.33B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$2.36B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	$-10.50M	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	$-1.20M	USD	Point-in-time
Treasury stock, at cost (16,216,411 shares at June 30, 2022 and December 31, 2021)	`TreasuryStockValue`	$802.49M	USD	Point-in-time
Treasury stock, at cost (16,216,411 shares at June 30, 2022 and December 31, 2021)	`TreasuryStockValue`	$802.49M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-425.34M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-238.76M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$1.29B	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$1.72B	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$1.12B	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$2.30B	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$1.21B	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$399.50M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$1.44B	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$1.25B	USD	Point-in-time

Income Statement 82 line items

Line Item	Tag	Value	Unit	Period
Total revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	-	USD	1 Quarter
Total revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$6.41M	USD	2 Qtrs
Total revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$5.58M	USD	1 Quarter
Total revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	-	USD	2 Qtrs
Cost of sales	`CostOfGoodsAndServicesSold`	-	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$774.00K	USD	2 Qtrs
Cost of sales	`CostOfGoodsAndServicesSold`	$435.00K	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	-	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$144.65M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$119.67M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$62.01M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$74.52M	USD	1 Quarter
Selling, general and administrative	`GeneralAndAdministrativeExpense`	$62.77M	USD	2 Qtrs
Selling, general and administrative	`GeneralAndAdministrativeExpense`	$29.21M	USD	1 Quarter
Selling, general and administrative	`GeneralAndAdministrativeExpense`	$59.78M	USD	2 Qtrs
Selling, general and administrative	`GeneralAndAdministrativeExpense`	$28.26M	USD	1 Quarter
Total cost and expenses	`CostsAndExpenses`	$103.22M	USD	1 Quarter
Total cost and expenses	`CostsAndExpenses`	$91.22M	USD	1 Quarter
Total cost and expenses	`CostsAndExpenses`	$182.44M	USD	2 Qtrs
Total cost and expenses	`CostsAndExpenses`	$205.20M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-182.44M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-91.22M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-198.78M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-97.64M	USD	1 Quarter
Royalty income from gain on sale of oncology business	`GainLossOnSaleOfBusiness`	$2.00M	USD	2 Qtrs
Royalty income from gain on sale of oncology business	`GainLossOnSaleOfBusiness`	$2.70M	USD	1 Quarter
Royalty income from gain on sale of oncology business	`GainLossOnSaleOfBusiness`	$2.00M	USD	1 Quarter
Royalty income from gain on sale of oncology business	`GainLossOnSaleOfBusiness`	$5.41M	USD	2 Qtrs
Interest income (expense), net	`InvestmentIncomeNet`	$2.49M	USD	2 Qtrs
Interest income (expense), net	`InvestmentIncomeNet`	$1.79M	USD	1 Quarter
Interest income (expense), net	`InvestmentIncomeNet`	$248.00K	USD	2 Qtrs
Interest income (expense), net	`InvestmentIncomeNet`	$-92.00K	USD	1 Quarter
Other income, net	`OtherNonoperatingIncomeExpense`	$1.34M	USD	1 Quarter
Other income, net	`OtherNonoperatingIncomeExpense`	$4.31M	USD	2 Qtrs
Other income, net	`OtherNonoperatingIncomeExpense`	$6.52M	USD	1 Quarter
Other income, net	`OtherNonoperatingIncomeExpense`	$6.52M	USD	2 Qtrs
Net loss from continuing operations	`IncomeLossFromContinuingOperations`	$-82.79M	USD	1 Quarter
Net loss from continuing operations	`IncomeLossFromContinuingOperations`	$-186.58M	USD	2 Qtrs
Net loss from continuing operations	`IncomeLossFromContinuingOperations`	$-173.67M	USD	2 Qtrs
Net loss from continuing operations	`IncomeLossFromContinuingOperations`	$-91.81M	USD	1 Quarter
Net (loss) income from discontinued operations, net of tax	`IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity`	$-3.43M	USD	1 Quarter
Net (loss) income from discontinued operations, net of tax	`IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity`	$1.96B	USD	2 Qtrs
Net (loss) income from discontinued operations, net of tax	`IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity`	-	USD	2 Qtrs
Net (loss) income from discontinued operations, net of tax	`IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity`	-	USD	1 Quarter
Net (loss) income	`NetIncomeLoss`	$-94.77M	USD	1 Quarter
Net (loss) income	`NetIncomeLoss`	$1.79B	USD	2 Qtrs
Net (loss) income	`NetIncomeLoss`	$-186.58M	USD	2 Qtrs
Net (loss) income	`NetIncomeLoss`	$-86.22M	USD	1 Quarter
Net (loss) income	`NetIncomeLoss`	$1.87B	USD	1 Quarter
Net (loss) income	`NetIncomeLoss`	$-91.81M	USD	1 Quarter
Net loss from continuing operations per share - basic (in usd per share)	`IncomeLossFromContinuingOperationsPerBasicShare`	$-3.41	USD	2 Qtrs
Net loss from continuing operations per share - basic (in usd per share)	`IncomeLossFromContinuingOperationsPerBasicShare`	$-1.68	USD	1 Quarter
Net loss from continuing operations per share - basic (in usd per share)	`IncomeLossFromContinuingOperationsPerBasicShare`	$-2.66	USD	2 Qtrs
Net loss from continuing operations per share - basic (in usd per share)	`IncomeLossFromContinuingOperationsPerBasicShare`	$-1.36	USD	1 Quarter
Net loss from continuing operations per share - diluted (in usd per share)	`IncomeLossFromContinuingOperationsPerDilutedShare`	$-1.36	USD	1 Quarter
Net loss from continuing operations per share - diluted (in usd per share)	`IncomeLossFromContinuingOperationsPerDilutedShare`	$-1.68	USD	1 Quarter
Net loss from continuing operations per share - diluted (in usd per share)	`IncomeLossFromContinuingOperationsPerDilutedShare`	$-2.66	USD	2 Qtrs
Net loss from continuing operations per share - diluted (in usd per share)	`IncomeLossFromContinuingOperationsPerDilutedShare`	$-3.41	USD	2 Qtrs
Net (loss) income from discontinued operations per share - basic (in usd per share)	`IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare`	-	USD	2 Qtrs
Net (loss) income from discontinued operations per share - basic (in usd per share)	`IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare`	$-0.06	USD	1 Quarter
Net (loss) income from discontinued operations per share - basic (in usd per share)	`IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare`	-	USD	1 Quarter
Net (loss) income from discontinued operations per share - basic (in usd per share)	`IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare`	$30.05	USD	2 Qtrs
Net (loss) income from discontinued operations per share - diluted (in usd per share)	`IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare`	-	USD	1 Quarter
Net (loss) income from discontinued operations per share - diluted (in usd per share)	`IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare`	$-0.06	USD	1 Quarter
Net (loss) income from discontinued operations per share - diluted (in usd per share)	`IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare`	-	USD	2 Qtrs
Net (loss) income from discontinued operations per share - diluted (in usd per share)	`IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare`	$30.05	USD	2 Qtrs
Net (loss) income per share - basic (in usd per share)	`EarningsPerShareBasic`	$-1.68	USD	1 Quarter
Net (loss) income per share - basic (in usd per share)	`EarningsPerShareBasic`	$27.39	USD	2 Qtrs
Net (loss) income per share - basic (in usd per share)	`EarningsPerShareBasic`	$-1.41	USD	1 Quarter
Net (loss) income per share - basic (in usd per share)	`EarningsPerShareBasic`	$-3.41	USD	2 Qtrs
Net (loss) income per share - diluted (in usd per share)	`EarningsPerShareDiluted`	$-3.41	USD	2 Qtrs
Net (loss) income per share - diluted (in usd per share)	`EarningsPerShareDiluted`	$27.39	USD	2 Qtrs
Net (loss) income per share - diluted (in usd per share)	`EarningsPerShareDiluted`	$-1.68	USD	1 Quarter
Net (loss) income per share - diluted (in usd per share)	`EarningsPerShareDiluted`	$-1.41	USD	1 Quarter
Weighted-average number of common shares used in computing net loss per share from continuing operations, net (loss) income from discontinued operations and net (loss) income per share - basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	65.28M	shares	2 Qtrs
Weighted-average number of common shares used in computing net loss per share from continuing operations, net (loss) income from discontinued operations and net (loss) income per share - basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	54.68M	shares	2 Qtrs
Weighted-average number of common shares used in computing net loss per share from continuing operations, net (loss) income from discontinued operations and net (loss) income per share - basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	61.07M	shares	1 Quarter
Weighted-average number of common shares used in computing net loss per share from continuing operations, net (loss) income from discontinued operations and net (loss) income per share - basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	54.80M	shares	1 Quarter
Weighted-average number of common shares used in computing net loss per share from continuing operations, net (loss) income from discontinued operations and net (loss) income per share - diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	61.07M	shares	1 Quarter
Weighted-average number of common shares used in computing net loss per share from continuing operations, net (loss) income from discontinued operations and net (loss) income per share - diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	54.68M	shares	2 Qtrs
Weighted-average number of common shares used in computing net loss per share from continuing operations, net (loss) income from discontinued operations and net (loss) income per share - diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	54.80M	shares	1 Quarter
Weighted-average number of common shares used in computing net loss per share from continuing operations, net (loss) income from discontinued operations and net (loss) income per share - diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	65.28M	shares	2 Qtrs

Cash Flow Statement 86 line items

Line Item	Tag	Value	Unit	Period
Net (loss) income	`NetIncomeLoss`	$-94.77M	USD	1 Quarter
Net (loss) income	`NetIncomeLoss`	$1.79B	USD	2 Qtrs
Net (loss) income	`NetIncomeLoss`	$-186.58M	USD	2 Qtrs
Net (loss) income	`NetIncomeLoss`	$-86.22M	USD	1 Quarter
Net (loss) income	`NetIncomeLoss`	$1.87B	USD	1 Quarter
Net (loss) income	`NetIncomeLoss`	$-91.81M	USD	1 Quarter
Less: Net income from discontinued operations	`IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity`	$-3.43M	USD	1 Quarter
Less: Net income from discontinued operations	`IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity`	$1.96B	USD	2 Qtrs
Less: Net income from discontinued operations	`IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity`	-	USD	2 Qtrs
Less: Net income from discontinued operations	`IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity`	-	USD	1 Quarter
Net loss from continuing operations	`IncomeLossFromContinuingOperations`	$-82.79M	USD	1 Quarter
Net loss from continuing operations	`IncomeLossFromContinuingOperations`	$-186.58M	USD	2 Qtrs
Net loss from continuing operations	`IncomeLossFromContinuingOperations`	$-173.67M	USD	2 Qtrs
Net loss from continuing operations	`IncomeLossFromContinuingOperations`	$-91.81M	USD	1 Quarter
Depreciation and amortization	`OtherDepreciationAndAmortization`	$4.77M	USD	2 Qtrs
Depreciation and amortization	`OtherDepreciationAndAmortization`	$4.83M	USD	2 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	$26.68M	USD	2 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	$29.74M	USD	2 Qtrs
Net amortization of premium (accretion of discount) on marketable securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$-3.42M	USD	2 Qtrs
Net amortization of premium (accretion of discount) on marketable securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$-1.38M	USD	2 Qtrs
Loss on disposal of property and equipment	`GainLossOnSaleOfPropertyPlantEquipment`	$-12.00K	USD	2 Qtrs
Loss on disposal of property and equipment	`GainLossOnSaleOfPropertyPlantEquipment`	$-10.00K	USD	2 Qtrs
Non-cash operating lease expense	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$4.76M	USD	2 Qtrs
Non-cash operating lease expense	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$4.92M	USD	2 Qtrs
Accounts receivable, net	`IncreaseDecreaseInContractWithCustomerAsset`	$1.60M	USD	2 Qtrs
Accounts receivable, net	`IncreaseDecreaseInContractWithCustomerAsset`	-	USD	2 Qtrs
Inventory	`IncreaseDecreaseInInventories`	$4.06M	USD	2 Qtrs
Inventory	`IncreaseDecreaseInInventories`	-	USD	2 Qtrs
Other receivables	`IncreaseDecreaseInOtherReceivables`	$-1.67M	USD	2 Qtrs
Other receivables	`IncreaseDecreaseInOtherReceivables`	$8.13M	USD	2 Qtrs
Prepaid expenses and other current and non-current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$8.45M	USD	2 Qtrs
Prepaid expenses and other current and non-current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$3.56M	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-5.56M	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-7.24M	USD	2 Qtrs
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities`	$-3.58M	USD	2 Qtrs
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities`	$-2.55M	USD	2 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$-5.55M	USD	2 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$-3.63M	USD	2 Qtrs
Other non-current liabilities	`IncreaseDecreaseInOtherNoncurrentLiabilities`	$779.00K	USD	2 Qtrs
Other non-current liabilities	`IncreaseDecreaseInOtherNoncurrentLiabilities`	-	USD	2 Qtrs
Net cash used in operating activities - continuing operations	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-171.96M	USD	2 Qtrs
Net cash used in operating activities - continuing operations	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-159.23M	USD	2 Qtrs
Net cash used in operating activities - discontinued operations	`CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations`	-	USD	2 Qtrs
Net cash used in operating activities - discontinued operations	`CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations`	$-78.81M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-238.04M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-171.96M	USD	2 Qtrs
Purchases of marketable securities	`PaymentsToAcquireAvailableForSaleSecuritiesDebt`	$607.75M	USD	2 Qtrs
Purchases of marketable securities	`PaymentsToAcquireAvailableForSaleSecuritiesDebt`	$498.90M	USD	2 Qtrs
Proceeds from maturities and sales of marketable securities	`ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities`	$273.15M	USD	2 Qtrs
Proceeds from maturities and sales of marketable securities	`ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities`	$668.72M	USD	2 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$1.26M	USD	2 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$4.73M	USD	2 Qtrs
Net cash provided by (used in) investing activities - continuing operations	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-227.01M	USD	2 Qtrs
Net cash provided by (used in) investing activities - continuing operations	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$56.24M	USD	2 Qtrs
Net cash provided by investing activities - discontinued operations	`CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations`	$1.80B	USD	2 Qtrs
Net cash provided by investing activities - discontinued operations	`CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations`	-	USD	2 Qtrs
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$1.58B	USD	2 Qtrs
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$56.24M	USD	2 Qtrs
Payments on financing lease obligations	`FinanceLeasePrincipalPayments`	$164.00K	USD	2 Qtrs
Payments on financing lease obligations	`FinanceLeasePrincipalPayments`	$170.00K	USD	2 Qtrs
Purchase of treasury stock	`PaymentsForRepurchaseOfCommonStock`	-	USD	2 Qtrs
Purchase of treasury stock	`PaymentsForRepurchaseOfCommonStock`	$529.05M	USD	2 Qtrs
Net proceeds from stock option exercises and employee stock purchase plan	`ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions`	$1.30M	USD	2 Qtrs
Net proceeds from stock option exercises and employee stock purchase plan	`ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions`	$33.02M	USD	2 Qtrs
Net cash provided by (used in) financing activities - continuing operations	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$1.14M	USD	2 Qtrs
Net cash provided by (used in) financing activities - continuing operations	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$-496.20M	USD	2 Qtrs
Net cash provided by financing activities - discontinued operations	`CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations`	-	USD	2 Qtrs
Net cash provided by financing activities - discontinued operations	`CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations`	-	USD	2 Qtrs
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-496.20M	USD	2 Qtrs
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$1.14M	USD	2 Qtrs
Net change in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$841.69M	USD	2 Qtrs
Net change in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-114.58M	USD	2 Qtrs
Cash and cash equivalents at beginning of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$203.13M	USD	Point-in-time
Cash and cash equivalents at beginning of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$127.44M	USD	Point-in-time
Cash and cash equivalents at beginning of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$969.12M	USD	Point-in-time
Cash and cash equivalents at beginning of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$88.54M	USD	Point-in-time
Cash and cash equivalents at end of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$203.13M	USD	Point-in-time
Cash and cash equivalents at end of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$127.44M	USD	Point-in-time
Cash and cash equivalents at end of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$969.12M	USD	Point-in-time
Cash and cash equivalents at end of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$88.54M	USD	Point-in-time
Additions to property and equipment in accounts payable and accrued expenses	`CapitalExpendituresIncurredButNotYetPaid`	$56.00K	USD	2 Qtrs
Additions to property and equipment in accounts payable and accrued expenses	`CapitalExpendituresIncurredButNotYetPaid`	$11.00K	USD	2 Qtrs
Financing lease liabilities arising from obtaining financing lease assets	`RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability`	-	USD	2 Qtrs
Financing lease liabilities arising from obtaining financing lease assets	`RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability`	$511.00K	USD	2 Qtrs
Cash taxes paid	`IncomeTaxesPaidNet`	$6.20M	USD	2 Qtrs
Cash taxes paid	`IncomeTaxesPaidNet`	$1.84M	USD	2 Qtrs

Stockholders Equity 34 line items

Line Item	Tag	Value	Unit	Period
Beginning balance	`StockholdersEquity`	$1.29B	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$1.72B	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$1.12B	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$2.30B	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$1.21B	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$399.50M	USD	Point-in-time
Common stock issued under stock incentive plan and ESPP (in shares)	`StockIssuedDuringPeriodSharesStockOptionsExercised`	4,074.00	shares	2 Qtrs
Common stock issued under stock incentive plan and ESPP	`StockIssuedDuringPeriodValueStockOptionsExercised`	$1.29M	USD	1 Quarter
Common stock issued under stock incentive plan and ESPP	`StockIssuedDuringPeriodValueStockOptionsExercised`	$25.67M	USD	1 Quarter
Common stock issued under stock incentive plan and ESPP	`StockIssuedDuringPeriodValueStockOptionsExercised`	$15.00K	USD	1 Quarter
Common stock issued under stock incentive plan and ESPP	`StockIssuedDuringPeriodValueStockOptionsExercised`	$7.35M	USD	1 Quarter
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$11.16M	USD	1 Quarter
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$14.88M	USD	1 Quarter
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$14.85M	USD	1 Quarter
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$15.51M	USD	1 Quarter
Repurchase of common stock	`TreasuryStockValueAcquiredCostMethod`	$529.05M	USD	1 Quarter
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-141.00K	USD	1 Quarter
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-108.00K	USD	1 Quarter
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-6.55M	USD	1 Quarter
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-2.76M	USD	1 Quarter
Net (loss) income	`NetIncomeLoss`	$-94.77M	USD	1 Quarter
Net (loss) income	`NetIncomeLoss`	$1.79B	USD	2 Qtrs
Net (loss) income	`NetIncomeLoss`	$-186.58M	USD	2 Qtrs
Net (loss) income	`NetIncomeLoss`	$-86.22M	USD	1 Quarter
Net (loss) income	`NetIncomeLoss`	$1.87B	USD	1 Quarter
Net (loss) income	`NetIncomeLoss`	$-91.81M	USD	1 Quarter
Disposition of oncology business	`StockholdersEquityDispositionOfBusiness`	$-712.00K	USD	1 Quarter
Disposition of oncology business	`StockholdersEquityDispositionOfBusiness`	$-33.00K	USD	1 Quarter
Ending balance	`StockholdersEquity`	$1.29B	USD	Point-in-time
Ending balance	`StockholdersEquity`	$1.72B	USD	Point-in-time
Ending balance	`StockholdersEquity`	$1.12B	USD	Point-in-time
Ending balance	`StockholdersEquity`	$2.30B	USD	Point-in-time
Ending balance	`StockholdersEquity`	$1.21B	USD	Point-in-time
Ending balance	`StockholdersEquity`	$399.50M	USD	Point-in-time

Comprehensive Income 14 line items

Line Item	Tag	Value	Unit	Period
Net (loss) income	`NetIncomeLoss`	$-94.77M	USD	1 Quarter
Net (loss) income	`NetIncomeLoss`	$1.79B	USD	2 Qtrs
Net (loss) income	`NetIncomeLoss`	$-186.58M	USD	2 Qtrs
Net (loss) income	`NetIncomeLoss`	$-86.22M	USD	1 Quarter
Net (loss) income	`NetIncomeLoss`	$1.87B	USD	1 Quarter
Net (loss) income	`NetIncomeLoss`	$-91.81M	USD	1 Quarter
Unrealized loss on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-9.30M	USD	2 Qtrs
Unrealized loss on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-249.00K	USD	2 Qtrs
Unrealized loss on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-2.76M	USD	1 Quarter
Unrealized loss on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-141.00K	USD	1 Quarter
Comprehensive (loss) income	`ComprehensiveIncomeNetOfTax`	$-94.56M	USD	1 Quarter
Comprehensive (loss) income	`ComprehensiveIncomeNetOfTax`	$-195.88M	USD	2 Qtrs
Comprehensive (loss) income	`ComprehensiveIncomeNetOfTax`	$-86.36M	USD	1 Quarter
Comprehensive (loss) income	`ComprehensiveIncomeNetOfTax`	$1.79B	USD	2 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.